A word from our President
The last few months have been full of good news for adMare, and our teams have continued their mission to build companies, build ecosystems and build talent in the Canadian life sciences industry.
Our portfolio companies are doing well, with some reaching important milestones recently. We are also delighted to welcome five new companies to the adMare National Tx Accelerator, which I invite you to discover below.
adMare was honored to join British Columbia's Minister of Employment, Economic Development and Innovation, Brenda Bailey, in announcing the location of its additional Innovation Centre, which will open in the fall of 2025. Located close to many of the industry's leading companies, the Centre will support more than 20 early-stage ventures over the initial five-year period and contribute to the dynamism of Vancouver's ecosystem.
The adMare Academy continues to train the next generation, with the recent graduation of 22 participants from Cohort VI of the Executive Institute, while the Bioinnovation Science Programs Foundation and Industry Essentials successfully trained respectively 58 and 20 participants. These learners came from across Canada, representing the rich diversity of the country, and are now ready to contribute to the Canadian life science industry.
Respectfully,
Gordon C. McCauley
President & CEO, adMare BioInnovations
News from our porfolio companies
Abdera Therapeutics
Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer
Zymeworks
Zymeworks Announces FDA Clearance Of Investigational New Drug Application For ZW171, A Novel 2+1 T-Cell Targeting Bispecific Antibody For Mesothelin-Expressing Cancers
Domain Therapeutics
Domain Therapeutics strengthens its intellectual property for its series of Treg depleting anti-CCR8 antibodies, including best-in-class candidate DT-7012
Flosonics Medical
Flosonics Medical Secures $20 Million USD in Series C Funding Led by New Leaf Venture Partners to Accelerate Growth
News from our Accelerator
adMare BioInnovations Welcomes Five New Start-Ups in the National Tx Accelerator
"We're thrilled to welcome these ventures to our Accelerator," said Clara Ducord, Manager of the adMare National Tx Accelerator. "We want to help these companies innovate and grow; that's how the program works with partners in the sector, hopefully leading to advancements in life sciences and creating high-value economic opportunities nationwide."
Call for applications
Sweet Biopharma Day
Sweet Biopharma Day invites Canadian innovative start-ups to submit their application to be one of the 16 promising Canadian biotech companies, the famous "Sweet 16". Applications must be submitted no later than Tuesday, September 3, 2024.
adMare BioInnovations Expands with New Wet Laboratory Space in Vancouver
adMare has entered a long-term lease at the M4 Main Alley site, where an entire floor will be designed into flexible, turn-key lab space. This new facility will support more than 20 early-stage ventures over the initial five-year period. In addition to the support of JEDI, this project is made possible through the collaboration of many partners within the ecosystem, including Life Sciences British Columbia, and Westbank Corp.
Life sciences: anchor companies as an international springboard for Quebec?
adMare Industry Builder Series with François Ravenelle - Inversago Pharma's inspiring journey.
NIBRT's biomanufacturing training initiatives with Killian O'Driscoll
Call for applications are opened for Cohort VII of the adMare Executive Institute
Graduation of Cohort VI of the adMare Executive Institute
Successful completion of the latest cohorts of the BioInnovation Scientist (BIS) Programs
adMare BioInnovations
Vancouver
2405 Wesbrook Mall
Vancouver, British Columbia, Canada
V6T 1Z3
Toronto
100-101 College St
Toronto, Ontario, Canada
M5G 1L7, CA
Montreal
7171 Frederick-Banting
Montréal, Québec, Canada
H4S 1Z9
 |